Peptide Based Imaging Agents for HER2 Imaging in Oncology
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Molecular Imaging
- Vol. 19
Abstract
Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has approved receptor-based therapies including trastuzumab and pertuzumab that can significantly increase the likelihood of survival. Current methods to determine HER2 status include biopsies with immunohistochemical staining and/or fluorescence in situ hybridization. However, positron emission tomography (PET) imaging techniques using 89Zr-trastuzumab or 89Zr-pertuzumab are currently in clinical trials for a non-invasive, full body diagnostic approach. Although the antibodies have strong specificity to the HER2 positive lesions, challenges involving long post-injection time for imaging due to the blood circulation of the antibodies and matching of long-live isotopes leading to increased dose to the patient leave opportunities for alternative PET imaging probes. Peptides have been shown to allow for shorter injection-to-imaging time and can be used with shorter lived isotopes. HER2 specific peptides under development will help improve the diagnosis and potentially therapy options for HER2 positive breast cancer. Peptides showing specificity for HER2 could start widespread development of molecular imaging techniques for HER2 positive cancers.Keywords
This publication has 34 references indexed in Scilit:
- HER2 in Breast CancerAdvances in Anatomic Pathology, 2014
- Affinity Maturation of an ERBB2-Targeted SPECT Imaging Peptide by In Vivo Phage DisplayMolecular Imaging and Biology, 2014
- HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor GrowthIn VivoMolecular Cancer Therapeutics, 2013
- Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of CancerTheranostics, 2012
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor–Expressing Breast CarcinomasClinical Cancer Research, 2007
- Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeuticsThe FASEB Journal, 2005
- Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cellsThe FASEB Journal, 2002
- Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivoNature Biotechnology, 2000